Jennifer Liu, Chief of Cardiology at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Reduced echo monitoring every 6 months is safe and feasible for low risk HER2+ BC patients, per Anthony Yu et al.
A key step toward evidence-based, risk-adapted monitoring.”
Tharshini Ramalingam, JACC Cardio-oncology Assistant Editor, shared this post, adding:
“Congratulations Jennifer and Anthony on this important study !”
Title: Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
Authors: Anthony F Yu, Chau T Dang, Chaya S Moskowitz, Akriti Mishra Meza, Patricia DeFusco, Eric Oligino, Carol L Chen, Rachel Sanford, Pamela Drullinsky, Jacqueline Bromberg, Serena Wong, Shanu Modi, Justine Jorgensen, Kevin C Oeffinger, Richard M Steingart, Jennifer E Liu
Read OncoDaily’s Special Article: “Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health”
